Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)

SHA:600420 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	5,109	6,212	5,973	6,148	4,284	3,720
Short-Term Investments	-	1,431	-	-	-	-
Cash & Short-Term Investments	5,109	7,643	5,973	6,148	4,284	3,720
Cash Growth	-20.36%	27.97%	-2.86%	43.51%	15.18%	-27.97%
Accounts Receivable	1,609	1,361	2,051	2,656	3,048	2,602
Other Receivables	96.42	85.55	84.07	92.85	96.91	108.01
Receivables	1,705	1,447	2,135	2,748	3,144	2,710
Inventory	2,091	2,209	2,280	2,440	3,072	3,281
Prepaid Expenses	-	70.29	61.63	47.69	40.21	54.95
Other Current Assets	2,022	315.43	207.49	300.4	345.15	396.54
Total Current Assets	10,928	11,684	10,657	11,684	10,886	10,162
Property, Plant & Equipment	5,527	5,550	5,885	6,246	6,511	6,409
Long-Term Investments	399.21	1,316	1,431	376.22	370.77	382.29
Goodwill	160.15	160.15	160.15	160.15	160.15	292.3
Other Intangible Assets	632.94	591.29	511.18	517.08	549.09	524.58
Long-Term Deferred Tax Assets	104.76	103.15	153.13	239.09	188.75	115.32
Long-Term Deferred Charges	306.14	333.66	331.74	227.83	144.74	169.53
Other Long-Term Assets	1,271	216.67	223.65	179.17	259.22	195.05
Total Assets	19,329	19,956	19,352	19,630	19,070	18,250
Accounts Payable	1,423	1,103	1,374	1,249	1,542	2,105
Accrued Expenses	208.71	1,420	1,595	1,675	1,670	468.15
Short-Term Debt	50.05	50.05	45.05	321.14	2,014	1,619
Current Portion of Long-Term Debt	10.79	1,031	-	48.37	539.63	144.99
Current Portion of Leases	-	8.86	10.6	9.86	40.13	49.4
Current Income Taxes Payable	130.14	72.51	29.95	37.94	30.86	23.84
Current Unearned Revenue	110.81	193.33	244.6	344.17	201.23	1,362
Other Current Liabilities	1,361	465.17	480.59	509.97	804.25	422.99
Total Current Liabilities	3,295	4,344	3,780	4,196	6,843	6,194
Long-Term Debt	-	-	1,031	2,955	1,547	1,988
Long-Term Leases	48.6	47.94	57.97	68.57	43	0.59
Long-Term Unearned Revenue	110.48	113.99	122.8	138.01	140.33	167.03
Long-Term Deferred Tax Liabilities	72.2	70.77	22.15	119.55	126.19	80.31
Other Long-Term Liabilities	56.96	56.96	-	-	-	-
Total Liabilities	3,583	4,634	5,014	7,478	8,700	8,431
Common Stock	1,341	1,341	1,341	1,172	1,027	1,027
Additional Paid-In Capital	5,204	5,204	5,204	3,587	2,545	2,545
Retained Earnings	7,021	6,660	5,845	5,287	4,762	4,300
Comprehensive Income & Other	-0.91	-0.91	-1.09	259.34	258.88	258.63
Total Common Equity	13,565	13,204	12,388	10,305	8,593	8,131
Minority Interest	2,180	2,118	1,950	1,847	1,777	1,688
Shareholders' Equity	15,746	15,322	14,338	12,153	10,370	9,819
Total Liabilities & Equity	19,329	19,956	19,352	19,630	19,070	18,250
Total Debt	109.44	1,138	1,145	3,403	4,184	3,802
Net Cash (Debt)	5,000	6,505	4,828	2,745	99.84	-82.31
Net Cash Growth	-5.62%	34.74%	75.89%	2649.36%	-	-
Net Cash Per Share	3.73	4.85	3.79	2.37	0.08	-0.07
Filing Date Shares Outstanding	1,341	1,341	1,341	1,172	1,027	1,027
Total Common Shares Outstanding	1,341	1,341	1,341	1,172	1,027	1,027
Working Capital	7,633	7,340	6,877	7,489	4,044	3,968
Book Value Per Share	10.11	9.85	9.24	8.57	8.11	7.92
Tangible Book Value	12,772	12,452	11,717	9,628	7,884	7,314
Tangible Book Value Per Share	9.52	9.28	8.74	7.99	7.42	7.12
Buildings	-	4,491	4,472	3,945	3,874	3,712
Machinery	-	8,453	8,370	8,184	7,920	7,428
Construction In Progress	-	142.68	101.35	642.37	585.52	575.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.